BioCentury | Aug 22, 2019
Distillery Techniques

Delivering mAbs to CNS metastases using polymer-based nanoparticles

TECHNIQUES CATEGORY: Drug delivery TECHNOLOGY: Polymers; nanoparticles A zwitterionic polymer-based nanoparticle system could enable delivery of therapeutic mAbs to cancer metastases in the CNS. The method involves encapsulating mAbs in nanoparticles formed by cross-linking methacryloyloxyethyl...
BioCentury | Oct 6, 2017
Preclinical News

New light on gamma secretase failures in AD

...think semagacestat does not inhibit the former proteolytic function but inhibits the latter pump-like function,” Masa...
BioCentury | Jun 27, 2017
Distillery Therapeutics

Neurology

...published online May 15, 2017 doi:10.1073/pnas.1700499114 CONTACT: Masashi Yanagisawa, University of Tsukuba, Ibaraki, Japan email: yanagisawa.masa.fu@u.tsukuba.ac.jp Winnie...
BioCentury | Jan 18, 2017
Distillery Therapeutics

Infectious disease

...published online Dec. 30, 2016 doi:10.7554/eLife.21055 CONTACT: Masashi Yanagisawa, University of Tsukuba, Tsukuba, Japan email: yanagisawa.masa.fu@u.tsukuba.ac.jp Winnie...
BioCentury | Feb 11, 2013
Finance

Bubbling up in Japan

...said. "When the bubble bursts, that will be the time U.S. investors may come in." Masa...
BioCentury | Apr 23, 2012
Strategy

Cracking the code

...deal with Chugai Pharmaceutical Co. Ltd. , which is majority owned by Roche . CEO Masa...
BioCentury | Oct 6, 2011
Distillery Techniques

Technology: Drug platforms

...Okano, Keio University, Tokyo, Japan e-mail: hidokano@a2.keio.jp Contact: Masaya Nakamura, same affiliation as above e-mail: masa@sc.itc.keio.ac.jp BC...
BioCentury | Mar 21, 2011
Finance

Eyes and ears

...Japanese rights. Sirinakis and managing partner Sinclair Dunlop previously co-invested a $30 million fund for Masa...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...Okano Keio University, Tokyo, Japan e-mail: hidokano@sc.itc.keio.ac.jp Contact: Masaya Nakamura, same affiliation as above e-mail: masa@sc.itc.keio.ac.jp...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Neurology

...Okano Keio University, Tokyo, Japan e-mail: hidokano@sc.itc.keio.ac.jp Contact: Masaya Nakamura, same affiliation as above e-mail: masa@sc.itc.keio.ac.jp BC...
Items per page:
1 - 10 of 14
BioCentury | Aug 22, 2019
Distillery Techniques

Delivering mAbs to CNS metastases using polymer-based nanoparticles

TECHNIQUES CATEGORY: Drug delivery TECHNOLOGY: Polymers; nanoparticles A zwitterionic polymer-based nanoparticle system could enable delivery of therapeutic mAbs to cancer metastases in the CNS. The method involves encapsulating mAbs in nanoparticles formed by cross-linking methacryloyloxyethyl...
BioCentury | Oct 6, 2017
Preclinical News

New light on gamma secretase failures in AD

...think semagacestat does not inhibit the former proteolytic function but inhibits the latter pump-like function,” Masa...
BioCentury | Jun 27, 2017
Distillery Therapeutics

Neurology

...published online May 15, 2017 doi:10.1073/pnas.1700499114 CONTACT: Masashi Yanagisawa, University of Tsukuba, Ibaraki, Japan email: yanagisawa.masa.fu@u.tsukuba.ac.jp Winnie...
BioCentury | Jan 18, 2017
Distillery Therapeutics

Infectious disease

...published online Dec. 30, 2016 doi:10.7554/eLife.21055 CONTACT: Masashi Yanagisawa, University of Tsukuba, Tsukuba, Japan email: yanagisawa.masa.fu@u.tsukuba.ac.jp Winnie...
BioCentury | Feb 11, 2013
Finance

Bubbling up in Japan

...said. "When the bubble bursts, that will be the time U.S. investors may come in." Masa...
BioCentury | Apr 23, 2012
Strategy

Cracking the code

...deal with Chugai Pharmaceutical Co. Ltd. , which is majority owned by Roche . CEO Masa...
BioCentury | Oct 6, 2011
Distillery Techniques

Technology: Drug platforms

...Okano, Keio University, Tokyo, Japan e-mail: hidokano@a2.keio.jp Contact: Masaya Nakamura, same affiliation as above e-mail: masa@sc.itc.keio.ac.jp BC...
BioCentury | Mar 21, 2011
Finance

Eyes and ears

...Japanese rights. Sirinakis and managing partner Sinclair Dunlop previously co-invested a $30 million fund for Masa...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...Okano Keio University, Tokyo, Japan e-mail: hidokano@sc.itc.keio.ac.jp Contact: Masaya Nakamura, same affiliation as above e-mail: masa@sc.itc.keio.ac.jp...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Neurology

...Okano Keio University, Tokyo, Japan e-mail: hidokano@sc.itc.keio.ac.jp Contact: Masaya Nakamura, same affiliation as above e-mail: masa@sc.itc.keio.ac.jp BC...
Items per page:
1 - 10 of 14